论文部分内容阅读
利妥昔单抗上市20多年以来，在临床实践中疗效和安全性良好。美国食品药品管理局（FDA）于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前，利妥昔单抗90 min静脉快速输注方案已在国外成熟应用，美国国立综合癌症网络（NCCN）指南中也推荐第1个疗程利妥昔单抗输注未出现输注反应的患者，后续疗程可进行利妥昔单抗90 min静脉快速输注。我国也有研究数据证实了利妥昔单抗90 min静脉快速输注方案的安全性和耐受性。因此，基于国内外循证医学证据，为了提高患者的就诊质量以及节约医疗成本，本专家共识推荐，对于首次输注未发生明显不良反应的患者，后续疗程可使用利妥昔单抗90 min静脉快速输注方案。“,”Rituximab has received marketing authorization for more than 20 years and has good efficacy and safety in clinical practice. The U.S. Food and Drug Administration (FDA) approved a rapid infusion of rituximab for the second and subsequent cycles of treatment in 2012. Nowadays, the 90-minute rapid infusion of rituximab in foreign countries has been maturely applied. The National Comprehensive Cancer Network (NCCN) guidelines also recommend a 90-minute rapid infusion of rituximab for the second and subsequent cycles of rituximab to patients who do not experience infusion-related reactions during the first cycle of rituximab infusion. In China, there are emerging research data confirming the safety and tolerability of the 90-minute rapid infusion of rituximab. Therefore, based on evidences from evidence-based medicine at home and abroad, in order to improve the quality of patients' hospital visits and further save healthcare costs, this expert consensus recommends the use of 90-minute rapid infusion of rituximab for patients who have no obvious adverse reactions during the first cycle of infusion.